• Tetrahedral DNA Frameworks Improve Enzymatic Synthesis

  2026-10-07

  The reference study presents tetrahedral DNA nanostructures as an ordered interface for improving primer accessibility during enzymatic oligonucleotide synthesis. Reported results include higher catalytic performance, fewer deletion errors in patterned sequences, and a 96.82% stepwise yield in a 60-nucleotide DNA information-storage demonstration, although broader applicability remains to be established.

• Maraviroc and CCR5: Evidence Across Research Contexts

  2026-10-07

  Maraviroc, also known as UK-427857, is a selective CCR5 antagonist best known in the supplied material for HIV-1 entry research. A recent rheumatoid arthritis study extends the research context to CCR5-positive extracellular vesicles, while evidence for neuroinflammation modulation remains preliminary and requires independent validation.

• Trametinib and the Logic of MAPK Resistance

  2026-10-06

  Trametinib (GSK1120212) is more than a MEK inhibitor: it is a useful perturbational lens for studying how melanoma cells rewire signaling under MAPK pressure. This article connects its canonical pharmacology with multi-omics evidence on ARID1A-dependent resistance and explains how to interpret pathway, cell-cycle, and survival readouts without overstating causality.

• Carboxylesterase Confounds Mitochondrial H₂O₂ Assays

  2026-10-06

  Miwa and colleagues showed that Amplex Red can be converted to resorufin by carboxylesterase without hydrogen peroxide, horseradish peroxidase, or oxygen, challenging a widely used assumption in mitochondrial ROS measurement. The finding places greater emphasis on matrix-specific controls and on distinguishing genuine H₂O₂ release from probe metabolism in tissue and cell preparations.

• ZK53 and Human Mitochondrial ClpP Research

  2026-10-05

  ZK53 is described by APExBIO as a selective human mitochondrial serine protease ClpP activator with anticancer research applications. This overview separates supplier-reported biochemical and cellular findings from the independently supplied Nature study on fasting-responsive translation, and examines evidence strength, mechanistic interpretation, and translational limits.

• ML385 and NRF2 Signaling: Evidence and Limits

  2026-10-05

  ML385 is a research compound used to investigate NRF2 signaling pathway inhibition, oxidative stress modulation, ferroptosis, and cancer therapeutic resistance. A 2024 mouse study used ML385 to test whether artemisinin’s protection against diabetic cognitive impairment depended on NRF2 activation. The findings support pathway involvement, but model specificity, pharmacological selectivity, and limited cross-disease evidence constrain broader conclusions.

• Bestatin (Ubenimex): Evidence and Research Context

  2026-10-04

  Bestatin, also known as Ubenimex, is a research compound described by APExBIO as an inhibitor of several aminopeptidases. This overview separates supplier-reported potency and application claims from findings in a peer-reviewed Immunity study on viral RIPK3 degradation. The available evidence supports Bestatin as a mechanistic research tool for aminopeptidase biology, but the supplied viral study does not test Bestatin and cannot establish antiviral, necroptosis, or therapeutic effects for the compound.

• 2% Phosphotungstic Acid: From Image to Evidence

  2026-10-03

  Explore how 2% Phosphotungstic Acid supports negative-stain electron microscopy and how images should be interpreted alongside biochemical and functional evidence. This article uses coronavirus glycan research to define what morphology can show, what it cannot establish, and why that distinction matters.

• Demethyleneberberine for NSCLC Research

  2026-10-02

  Demethyleneberberine (DMB) supports a mechanism-led workflow that connects NSCLC viability, cell-cycle arrest, senescence, migration, and c-Myc/HIF-1α signaling. This practical guide covers formulation, assay sequencing, pathway validation, troubleshooting, and cautious extension into inflammatory, hepatic, and neurodegenerative models.

• ABT-263 (Navitoclax): From Mechanism to Translation

  2026-10-01

  ABT-263 (Navitoclax) is more than a potent Bcl-2-family inhibitor: it is a strategic perturbation tool for mapping mitochondrial apoptotic dependence. This thought-leadership guide connects mechanism, assay design, biomarker logic, and translational model selection while defining what the evidence does—and does not—support.

• Latrunculin A for Actin Mechanobiology Assays

  2026-10-01

  Latrunculin A gives researchers reversible control over actin assembly, enabling acute tests of cytoskeletal dependence in stiffness, migration, morphology, and axon-growth assays. Its temporal precision complements genetic mechanotransduction studies by separating upstream sensing from downstream actin remodeling.

• Acetylcholine Chloride and Gut-Brain Translation

  2026-09-30

  A translational framework for using Acetylcholine Chloride to dissect gut–vagus–brain cholinergic signaling, interpret recent Bacteroides fragilis epilepsy findings, and design more rigorous mechanistic assays.

• Estradiol Benzoate: ERα Assay Workflows

  2026-09-30

  Use Estradiol Benzoate as a defined estrogen receptor alpha agonist for connecting receptor binding, pathway activation, and model-specific validation. This guide combines practical stock preparation and assay controls with a structure-based screening perspective that helps separate mechanistic evidence from unsupported translational claims.

• Of Chloroquine and COVID-19: Evidence and Limits

  2026-09-29

  Touret and de Lamballerie place early enthusiasm for chloroquine against a broader record of antiviral research, showing why cell-culture activity and isolated animal findings cannot substitute for controlled clinical evidence. The commentary is especially useful for designing translational studies that separate antiviral signal, host-directed effects, toxicity, and disease-specific outcomes.

• CLEC5A, ISG20, and Causal Inference in Atherosclerosis

  2026-09-29

  Zhang et al. integrate GEO transcriptomic data, eQTL evidence, Mendelian randomization, and experimental validation to investigate immune regulators of atherosclerosis. The study identifies CLEC5A and ISG20 as positively associated with disease risk and provides complementary cell and mouse evidence that ISG20 is enriched in macrophage- and endothelial-associated plaque regions.

8117 records 1/542 page Next 12345 下5页 Last page